Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sitagliptin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-44. [Sitagliptin - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 444. 2016 Indexing Status Subject indexing assigned by CRD MeSH Dipeptidyl-Peptidase IV Inhibitors; Germany; Humans; Hypoglycemic Agents; Sitagliptin Phosphate; State Medicine Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32017000120 Date abstract record published 18/01/2017 |